What is the current Infectious Disease Therapeutics market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Infectious Disease Therapeutics market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Infectious Disease Therapeutics market?

Increasing prevalence of infectious diseases and advances in treatment options drive market growth.

What are the major challenges facing the Infectious Disease Therapeutics market?

Antimicrobial resistance and high development costs are significant challenges.

Which regions are leaders in the Infectious Disease Therapeutics market?

North America and Europe are current regional leaders due to high healthcare expenditure.

Who are the top companies in the Infectious Disease Therapeutics market?

Top companies include Pfizer, Merck, and Gilead Sciences, driving future outlook.

What future opportunities exist in the Infectious Disease Therapeutics market?

Emerging markets and innovative technologies offer significant future opportunities.

How does technology impact the Infectious Disease Therapeutics market?

Advances in technology improve treatment options and patient outcomes.

What is the current regulatory landscape for the Infectious Disease Therapeutics market?

Stringent regulations and safety protocols govern market development and approval.

What is the expected future outlook for the Infectious Disease Therapeutics market size?

The market size is expected to reach USD 2.5 billion by 2033, driven by growth forecast.

Infectious Disease Therapeutics Growth, Trends & Forecast Outlook 2033

Infectious Disease Therapeutics by Type (/> Drugs, Vaccines), by Application (/> HIV/AIDS, Influenza, Hepatitis, Malaria, Tuberculosis, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $123.4 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $123.4 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Infectious Disease Therapeutics Market Size | CAGR 10.2 Forecast 2033

Infectious Disease Therapeutics Growth, Trends & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $123.4 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $123.4 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Infectious Disease Therapeutics Market Overview

The Infectious Disease Therapeutics market refers to the industry focused on developing and marketing treatments for infectious diseases, which remains a critical area of healthcare given the ongoing impact of such diseases worldwide. As the Infectious Disease Therapeutics market size is anticipated to reach $64.8 billion by 2026, the growth outlook and market forecast indicate a promising industry expansion driven by advancements in medical technology and increasing awareness about infectious diseases. The scope of this market encompasses a broad range of therapeutics, including antibacterial, antiviral, antifungal, and antiparasitic drugs, highlighting the complexity and diversity of the infectious disease therapeutics landscape.

Loading chart…

The Infectious Disease Therapeutics market is expected to experience a significant growth rate, with a compound annual growth rate (CAGR) of 7.3% from 2026 to 2033, driven by macro drivers such as an increasing prevalence of infectious diseases, technological advancements in drug development, and rising healthcare expenditures. Key forces shaping the industry include technology shifts towards more targeted and effective therapies, regulatory frameworks that encourage innovation while ensuring safety and efficacy, and consumer behavior trends that prioritize health and wellness. The largest region in the Infectious Disease Therapeutics market is North America, while the fastest-growing region is anticipated to be Asia-Pacific, driven by rapid economic growth, large populations, and increasing access to healthcare services. Understanding these dynamics is crucial for market forecast accuracy and strategic planning in the infectious disease therapeutics sector.

Report Overview

Report Attribute	Details
Market size value in 2025	123.40 million
Revenue forecast in 2033	268.39 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis AG; Gilead; GlaxoSmithKline plc; Janssen Pharmaceutical Inc.; F. Hoffmann-La Roche Ltd.; BioCryst Pharmaceuticals Inc.; Merck & Co. Inc.; Boehringer Ingelheim GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Infectious Disease Therapeutics market is poised for significant growth, driven by various factors. The market dynamics are influenced by several key elements that impact the Infectious Disease Therapeutics market size and growth forecast.

Growth Drivers2 items

Increasing prevalence of infectious diseases, such as COVID-19, tuberculosis, and HIV, is driving demand for effective treatments, thereby contributing to the growth of the Infectious Disease Therapeutics market

Advances in technological innovations, including gene editing and immunotherapy, are expanding the range of available treatments, further fueling the growth forecast of the Infectious Disease Therapeutics market

Restraints2 items

High development costs and lengthy regulatory approval processes are hindering the growth of new Infectious Disease Therapeutics market entrants, limiting the Infectious Disease Therapeutics market size

Increasing antimicrobial resistance is reducing the effectiveness of existing treatments, creating challenges for the Infectious Disease Therapeutics market and impacting its growth forecast

Opportunities2 items

Growing demand for personalized medicine and targeted therapies is creating new opportunities for players in the Infectious Disease Therapeutics market, driving growth and increasing the Infectious Disease Therapeutics market size

Expanding emerging markets and increasing healthcare expenditure in developing countries are providing new avenues for growth in the Infectious Disease Therapeutics market, influencing the growth forecast

Challenges2 items

Intense competition among established players and new entrants is driving down prices and profit margins in the Infectious Disease Therapeutics market, affecting the Infectious Disease Therapeutics market size

Stringent regulatory requirements and evolving policies are creating uncertainty and challenges for companies operating in the Infectious Disease Therapeutics market, impacting the growth forecast

Market Segmentation

Loading chart…

The Infectious Disease Therapeutics market can be segmented by Type, which includes various therapeutic approaches such as antibacterial, antiviral, antifungal, and antiparasitic. Each of these types contributes to the overall market size, with the antibacterial segment being the largest due to the high prevalence of bacterial infections. The Infectious Disease Therapeutics segmentation by type helps in understanding the market dynamics and the potential for growth in each segment.

The market can also be segmented by Application, which includes hospital-acquired infections, community-acquired infections, and bioterrorism. The hospital-acquired infections segment holds a significant share of the market due to the increasing incidence of nosocomial infections. The Application segment is crucial in understanding the demand for infectious disease therapeutics in different settings and the potential for growth in each area. The market taxonomy of infectious disease therapeutics by application helps in identifying the key areas of focus for pharmaceutical companies and researchers.

Infectious Disease Therapeutics Segmentation Breakdown10 items

Type

/> Drugs

Vaccines

Application

/> HIV/AIDS

Influenza

Hepatitis

Malaria

Tuberculosis

Others

Regional Insights

Loading chart…

The Infectious Disease Therapeutics market growth is expected to vary across regions, driven by factors such as adoption, policies, investments, demographics, infrastructure, and ecosystem maturity. The largest region, North America, accounts for approximately 40% of the market share, driven by key drivers such as high investment in research and development, a well-established infrastructure, and a mature ecosystem.

The fastest-growing region is Asia Pacific, driven by factors such as increasing adoption of advanced therapies, government policies supporting healthcare infrastructure development, and a large and growing demographics. Other regions, such as Europe, Latin America, and Middle East & Africa, also contribute to the regional forecast, with key drivers including rising demand for infectious disease treatments, expanding healthcare services, and growing awareness about infectious diseases.

Key drivers for each region include: North America - high investment in research and development, well-established infrastructure, and mature ecosystem; Europe - rising demand for infectious disease treatments, expanding healthcare services, and growing awareness about infectious diseases; Asia Pacific - increasing adoption of advanced therapies, government policies supporting healthcare infrastructure development, and large and growing demographics; Latin America - expanding healthcare services, growing awareness about infectious diseases, and increasing investment in healthcare infrastructure; and Middle East & Africa - rising demand for infectious disease treatments, growing awareness about infectious diseases, and increasing investment in healthcare infrastructure.

Competitive Landscape

The Infectious Disease Therapeutics market exhibits a moderately consolidated structure, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Infectious Disease Therapeutics competitive landscape is characterized by high competition, with companies employing various strategies to differentiate themselves. Key competitive levers include pricing, distribution networks, and product innovation, with companies seeking to optimize their positions through strategic partnerships and investments.

Companies in the Infectious Disease Therapeutics market are adopting strategies such as M&A, partnerships, product launches, expansion, R&D, and localization to stay competitive. Competitive differentiation is achieved through technology, service models, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks, which can impact their profitability and market share. The following companies are notable for their strategic focus:

Novartis AG: regional expansion

Gilead: innovation pipeline

GlaxoSmithKline plc: premium pricing

Janssen Pharmaceutical Inc.: local manufacturing

F. Hoffmann-La Roche Ltd.: vertical integration

BioCryst Pharmaceuticals Inc.: OEM tie-ups

Key Infectious Disease Therapeutics Companies8 items

Novartis AG

Gilead

GlaxoSmithKline plc

Janssen Pharmaceutical Inc.

F. Hoffmann-La Roche Ltd.

BioCryst Pharmaceuticals Inc.

Merck & Co. Inc.

Boehringer Ingelheim GmbH

Market Ecosystem

The Infectious Disease Therapeutics ecosystem spans a complex network of participants, from upstream technology providers and suppliers to downstream channels and end users. This ecosystem can be broadly divided into three segments: upstream, midstream, and downstream. Upstream participants, such as raw material suppliers and technology providers, create the foundational elements for therapeutics. Midstream participants, including manufacturers and system integrators, develop and integrate these elements into final products. Downstream participants, comprising distributors, service providers, and end users, deliver and support these products in the market.

Raw material suppliers — provide active pharmaceutical ingredients

Technology providers — develop formulations and delivery systems

OEMs / manufacturers — produce therapeutic products

System integrators / EPCs — integrate therapies into treatment regimens

Distributors / channel partners — deliver products to healthcare settings

Regulators/standards bodies — oversee safety and efficacy standards

End users / buyers — prescribe and administer therapies to patients

Within the Infectious Disease Therapeutics ecosystem, value flows through the creation and capture of therapeutic products and services. Control points, such as regulatory approvals and reimbursement policies, influence the adoption of new therapies. Dependency risks, including input constraints and standards compliance, can impact the supply chain. Furthermore, switching costs, partnerships, and interoperability requirements can affect the flexibility of ecosystem participants. As the ecosystem differs by region, due to varying regulatory environments and healthcare systems, a nuanced understanding of these factors is essential for navigating the global Infectious Disease Therapeutics ecosystem, which is critical for conducting a thorough value chain analysis.

Recent Industry Insights

The Infectious Disease Therapeutics industry has witnessed significant developments over the last 12-18 months, shaping the Infectious Disease Therapeutics industry trends. Recent partnerships have been a key driver, with major pharmaceutical companies collaborating to develop innovative treatments. Notable mergers and acquisitions have also taken place, expanding the market presence of key players. Furthermore, several product and technology launches have been announced, offering new hope for the treatment and prevention of infectious diseases.

Regulatory changes have also played a crucial role, with updates to guidelines and policies influencing the development and approval of therapeutics. A shift in consumer and enterprise trends has been observed, with a growing focus on personalized medicine and digital health. Additionally, funding rounds and expansions have been secured by several companies, enabling the advancement of research and development in the field.

Analyst Overview

As the Lead Analyst for this study, I offer an expert view on the Infectious Disease Therapeutics market. The market attractiveness is moderate, driven by increasing demand for effective treatments against emerging infectious diseases. The competitive intensity is high, with several key players investing heavily in research and development. Looking at the long-term outlook, the Infectious Disease Therapeutics market outlook is promising, with opportunities for growth in emerging markets and innovative therapies.

The innovation landscape is rapidly evolving, with a focus on novel therapies and vaccines. However, the demand–supply balance is a concern, with potential shortages of critical treatments. Key risk factors include regulatory challenges, patent expirations, and supply chain disruptions. Overall, the market presents opportunities for growth, but players must navigate these challenges to succeed.

11 items

1. Executive Summary

2. Infectious Disease Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Infectious Disease Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Infectious Disease Therapeutics Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Drugs

6.1.2. Vaccines

6.2. Global Infectious Disease Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> HIV/AIDS

6.2.2. Influenza

6.2.3. Hepatitis

6.2.4. Malaria

6.2.5. Tuberculosis

6.2.6. Others

6.3. Global Infectious Disease Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Infectious Disease Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Infectious Disease Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Infectious Disease Therapeutics Market Competition by Key Manufacturers

8.1. Global Infectious Disease Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Infectious Disease Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Novartis AG

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Gilead

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GlaxoSmithKline plc

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Janssen Pharmaceutical Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. F. Hoffmann-La Roche Ltd.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. BioCryst Pharmaceuticals Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Merck & Co. Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Boehringer Ingelheim GmbH

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Infectious Disease Therapeutics Market

Figure 4: Global Infectious Disease Therapeutics Market: Drivers

Figure 5: Global Infectious Disease Therapeutics Market: Challenges

Figure 6: Global Infectious Disease Therapeutics Market: Trends

Figure 7: Global Infectious Disease Therapeutics Market: Opportunity

Figure 8: Global Infectious Disease Therapeutics Market: Restraint

Figure 9: Global Infectious Disease Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Infectious Disease Therapeutics Market Value (USD Million) By Region

Figure 15: Global Infectious Disease Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Infectious Disease Therapeutics Market Value (USD Million) By Region

Figure 23: Global Infectious Disease Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Infectious Disease Therapeutics Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Infectious Disease Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Infectious Disease Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Infectious Disease Therapeutics Market Value (USD Million) By Region

Table 10: Global Infectious Disease Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Infectious Disease Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Infectious Disease Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Infectious Disease Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Novartis AG Basic Information And Sales Area

Table 31: Novartis AG. Products Portfolio

Table 32: Gilead Basic Information And Sales Area

Table 33: Gilead. Products Portfolio

Table 34: GlaxoSmithKline plc Basic Information And Sales Area

Table 35: GlaxoSmithKline plc. Products Portfolio

Table 36: Janssen Pharmaceutical Inc. Basic Information And Sales Area

Table 37: Janssen Pharmaceutical Inc.. Products Portfolio

Table 38: F. Hoffmann-La Roche Ltd. Basic Information And Sales Area

Table 39: F. Hoffmann-La Roche Ltd.. Products Portfolio

Table 40: BioCryst Pharmaceuticals Inc. Basic Information And Sales Area

Table 41: BioCryst Pharmaceuticals Inc.. Products Portfolio

Table 42: Merck & Co. Inc. Basic Information And Sales Area

Table 43: Merck & Co. Inc.. Products Portfolio

Table 44: Boehringer Ingelheim GmbH Basic Information And Sales Area

Table 45: Boehringer Ingelheim GmbH. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Type

Table 47: Global Market Share (%) By Type (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Infectious Disease Therapeutics Market Value (USD Million) By Region

Table 51: Global Infectious Disease Therapeutics Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Type

Table 54: North America Market Value (USD Million) (2025-2032) By Application

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Type

Table 57: Europe Market Value (USD Million) (2025-2032) By Application

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Type

Table 63: South America Market Value (USD Million) (2025-2032) By Application

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Infectious Disease Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	123.40 million
Revenue forecast in 2033	268.39 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis AG; Gilead; GlaxoSmithKline plc; Janssen Pharmaceutical Inc.; F. Hoffmann-La Roche Ltd.; BioCryst Pharmaceuticals Inc.; Merck & Co. Inc.; Boehringer Ingelheim GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options